MAPT and Alzheimer disease: In fact, the biomarkers employed for the clinical confirmation of probable AD like Aβ42, t-tau, and p-tau either require a CSF sample, since this is the only body fluid where they have been validated [40], or need expensive assays employing the SimoaTM or Elecsys® technology for their robust assay in blood [41].